
Innovation Pharma’s Brilacidin inhibited novel Coronavirus by almost 90% at the lowest concentration tested to date in human lung cell line
On Jul. 20, 2020, Innovation Pharma reported receiving new data from ongoing lab testing being conducted at a U.S. Regional Biocontainment Laboratory (RBL). The data is helping to inform the planned Phase 2 clinical trial of Brilacidin for COVID-19, targeted to commence in Q4 2020.
The new data, using the same assay method, reveal Brilacidin exhibited a similarly potent inhibitory effect against SARS-CoV-2 at an even lower concentration in the same human lung epithelial cell line.
Tags:
Source: Innovation Pharmaceuticals
Credit:
